-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Alopecia Areata
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Alopecia Areata report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Alopecia Areata Drug Details: Upadacitinib (Rinvoq, Rim-Voq)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Vitiligo
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Vitiligo report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Vitiligo Drug Details: Upadacitinib (Rinvoq, Rim-Voq) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Hidradenitis Suppurativa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Hidradenitis Suppurativa report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Hidradenitis Suppurativa Drug Details: Upadacitinib (Rinvoq, Rim-Voq)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Oligoarticular Idiopathic Juvenile Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Oligoarticular Idiopathic Juvenile Arthritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Oligoarticular Idiopathic Juvenile Arthritis Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Polyarticular Juvenile Idiopathic Arthritis (PJIA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Polyarticular Juvenile Idiopathic Arthritis (PJIA) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Polyarticular Juvenile Idiopathic Arthritis...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Systemic Lupus Erythematosus report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Systemic Lupus Erythematosus Drug Details: Upadacitinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Upadacitinib ER in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib ER in Systemic-Onset Juvenile Idiopathic...
-
Analyst Opinions
Meeting the Needs of the Silver Segment in Personal Care
Meeting the Needs of the Silver Segment in Personal Care The phrase ‘silver (elderly) segment’ is defined as a distinct class of consumers, older than 55 years. According to GlobalData's macroeconomic data, accessed in November 2023, the Silver Generation consumers comprise 19% of the world population, of which women constitute over half of the older population. However, there are regional and country-level differences in the aging population demographics. Western European countries such as France and Germany, are among the top...
-
Product Insights
MRI Systems Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
MRI Systems Pipeline Market Report Overview Magnetic Resonance Imaging (MRI) generates clear and detailed images of internal organs and tissues using radiofrequency and a strong magnetic field. MRI is generally preferred for the diagnosis of brain and other neurological disorders. The 3T, 1.5T and 0.2-1.2T MRI systems have been tracked under this category. The MRI Systems pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report...
-
Sector Analysis
KRAS Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
The KRAS Market Report Overview The KRAS market size was $37.1 million in 2023. Factors such as product innovation will drive the market growth at a CAGR of more than 7% from 2023 to 2033. KRAS are devices used to inject contrast media agents into a patient's bloodstream. This process enables the visualization of various pathologies through X-ray, computed tomography, magnetic resonance, or other medical imaging devices. CT Injectors, MRI Injectors, and Angiographic Injectors have been included in this category....